Select A LocationAIVLOSIN® 17%
(Tylvalosin Medicated Premix)
Veterinary use only
Product Description
- Aivlosin® 17% contains 170 g/kg tylvalosin (supplied as tylvalosin tartrate) for oral use in medicating complete feed for swine
- For the treatment of Porcine Proliferative Enteropathy (PPE) associated with Lawsonia intracellularis in pigs
- Tylvalosin, the active ingredient in Aivlosin 17%, is a macrolide antibiotic
- Free-flowing granules
- Veterinary use only
- 10 kg bags
Key Features
- For the treatment of Porcine Proliferative Enteropathy (PPE)/ileitis associated with Lawsonia intracellularis infection in pigs
- Broad spectrum, potent macrolide not used in human health
- Accumulates rapidly in target tissues with intracellular concentrations many times extracellular levels
- Reliable dosing, consistent mixing
- Requires a prescription from a veterinarian
- No withdrawal period is required when treated according to the label
- Wide safety margin
Label Indications and Dosage
For Swine: Treatment of Porcine Proliferative Enteropathy (PPE) associated with Lawsonia intracellularis infection in pigs.
WARNINGS:
No withdrawal period is required when treated according to the label. Tylvalosin has been shown to cause hypersensitivity reactions in laboratory animals; therefore, people with known hypersensitivity to tylvalosin tartrate should avoid contact with this product.
When mixing and handling Aivlosin® 17%, avoid inhalation, oral exposure and direct contact with skin or eyes. Keep out of reach of children.
DESCRIPTION:
Aivlosin® 17% contains 170 g/kg tylvalosin (supplied as tylvalosin tartrate) for oral use in medicating complete feed for swine.
THERAPEUTIC CLASSIFICATION:
Tylvalosin, the active ingredient in Aivlosin 17%, is a macrolide antibiotic.
INDICATIONS:
For the treatment of Porcine Proliferative Enteropathy (PPE) associated with Lawsonia intracellularis in pigs.
TARGET SPECIES: Pigs.
DOSAGE AND ADMINISTRATION:
To reduce the development of antimicrobial resistance and maintain effectiveness, use this antibiotic prudently.
For Feed Manufacturing Use Only.
Do not feed undiluted.
Aivlosin® 17% must be thoroughly mixed into feeds before use.
Thoroughly mix 0.25 kg Aivlosin® 17% with 999.75 kg of complete feed to obtain a medicated feed with tylvalosin concentration of 0.00425% (42.5 g/1000 kg).
To aid in the even distribution of drug in the finished feed, add the full amount of Aivlosin® 17% into a small portion of the feed (at least 10 kg per tonne of finished feed) and mix. Blend this mixture into the remainder of the feed and mix thoroughly. Feed as the sole ration for 14 consecutive days.
CAUTIONS: Not for use in breeding animals.
The effects of tylvalosin on male and female reproductive performance, including pregnancy and lactation, have not been determined.
Do not use in feeds containing pellet binding agents with the exception of Lignosol (4%) and Agri-Colloid (0.3%).
Do not use in feeds containing bentonite.
Acute cases and severely diseased pigs with reduced food and water intake should be treated with a suitable injectable product. It is sound clinical practice to base treatment on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of target bacteria. Use of the product deviating from the instructions may increase the risk of development and selection of resistant bacteria and decrease the effectiveness of treatment with other macrolides due to the potential for cross-resistance.
ADVERSE REACTIONS:
No adverse reactions related to the drug were observed during clinical or target animal safety trials.
The Safety Data Sheet contains more detailed occupational safety information.
Withdrawal Period
- No withdrawal period is required when treated according to the label
Packaging
- 10 kg (22.07 lbs)
Formulation
- Free-flowing granules.
- Formulated for optimal dispersion, segregation, and stability in feed.
Storage
- Store in a cool dry place at or below 25ºC.
Swine
Caution: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.
For Swine: Control of porcine proliferative enteropathy (PPE) associated with Lawsonia intracellularis infection in groups of swine in buildings experiencing an outbreak of PPE.
Feeding Directions: Feed Type C medicated feed containing 38.6 grams tylvalosin/ton as the sole ration for 14 consecutive days.
Caution: To assure both food safety and responsible use in swine, concurrent use of tylvalosin Type A medicated article in medicated feed and tylvalosin or another macrolide in medicated drinking water or by any other route of administration should be avoided. Not for use in swine intended for breeding. The effects of tylvalosin on swine reproductive performance, pregnancy, and lactation have not been determined. VFDs for tylvalosin shall not be refilled.
Mixing Directions:
Preparation of Type B medicated feed containing 3,856 grams per ton (4,250 ppm) tylvalosin: Prepare tylvalosin Type B medicated feed in mash form only. To manufacture one ton of Type B medicated feed containing 3,856 g/ton (4,250 ppm) tylvalosin, mix 50 pounds of Aivlosin ® 17% Type A Medicated Article with 1950 pounds of non-medicated feed.
Preparation of Type C medicated feed containing 38.6 grams per ton (42.5 ppm) tylvalosin: To manufacture one ton of Type C medicated feed containing 38.6 g/ton (42.5 ppm) tylvalosin, mix 0.5 pound of Aivlosin® 17% Type A Medicated Article with 1999.5 pounds of non-medicated feed. To aid in the even distribution of drug in the finished feed, add the full amount of Aivlosin® 17% Type A Medicated Article into a small portion of the feed and mix. Blend this mixture into the remainder of the feed and mix thoroughly.
Pelleted Type C medicated feeds must bear an expiration date of 30 days after the date of manufacture.
Crumbled Type C medicated feeds must bear an expiration date of 7 days after the date of manufacture.
Antibacterial Warnings: Use of antibacterial drugs in the absence of a susceptible bacterial infection is unlikely to provide benefit to treated animals and may increase the development of drug-resistant bacteria.
User Safety Warnings: Not for use in humans. Keep out of reach of children. May cause skin irritation. Tylvalosin has been shown to cause hypersensitivity reactions in laboratory animals. People with known hypersensitivity to tylvalosin should avoid contact with this product. In case of accidental ingestion or inhalation, seek medical attention. When handling Aivlosin 17% Type A Medicated Article and preparing medicated feeds, avoid direct contact with the eyes and skin. Wear a dust mask, coveralls and impervious gloves when mixing and handling this product. Eye protection is recommended. In case of accidental eye exposure, wash eyes immediately with water and seek medical attention. If wearing contact lenses, immediately rinse the eyes first, then remove contact lenses and continue to rinse the eyes thoroughly and seek medical attention. In case of accidental skin exposure, wash contaminated skin thoroughly.
The Safety Data Sheet contains more detailed occupational safety information.
Available in Canada
The labeling contains complete use information, including any cautions and warnings. Always read, understand and follow the labeling and use directions. See the reverse side for use directions and additional information.